期刊文献+

多发性骨髓瘤细胞株RPMI8226上清液抑制成骨细胞早期分化 被引量:1

Suppression effect of supernatant from Mutiple myeloma cells RPMI8226 on the early stage of osteoblast differentiation
下载PDF
导出
摘要 目的:探讨多发性骨髓瘤细胞上清液在体外抑制成骨祖细胞早期分化的现象。方法:以多发性骨髓瘤细胞株RPMI8226上清加入到成骨祖细胞MC3T3-E1rBMP2诱导分化体系中培养6d后,计数碱性磷酸酶染色结节并以RT-PCR方法测定碱性磷酸酶和骨钙素mRNA水平。结果:MC3T3-E1诱导组和30%的骨髓瘤上清干预组的染色结节计数分别为(20.33±5.16)/低倍视野和(13.66±2.80)/低倍视野(P<0.05)。此外,30%上清干预组的碱性磷酸酶mRNA水平低于诱导组(P<0.05),而骨钙素mRNA水平差异无显著性(P>0.05)。结论:多发性骨髓瘤细胞RPMI8226上清液能够抑制rBMP2诱导的成骨祖细胞MC3T3-E1早期分化过程。 Objective: To investigate the effect of supernatant from Mutiple myeloma cells RPMI8226 on the early stage of osteoblast differentiation in vitro. Methods: The supernatant from Mutiple myeloma cells RPMI8226 was added into the system of the osteoblast differentiation which induced by rBMP2. After 6 days, osteoblast was collected to identify ALP staining nodule counting and mRNA of ALP and OC with RTPCR. Results: The ALP staining nodule counting was (13.66 ± 2.80) /L-visualis in supernatant interven- tion group and it was, (20.33 ± 5.16) /L-visualis in control group.The level of ALP mRNA was lower in supernatant intervention group than that of control group(P〈0.05). But the level of 0cmRNA in both group was indiscrimination(P〉0.05). Conclusion: The supernatant from Mutiple myeloma cells RPMI8226 inhibits the the early stage of osteoblast MC3T3-E1 differentiation which induced by rBMP2.
作者 胡倩 俞康
出处 《温州医学院学报》 CAS 2008年第3期213-216,共4页 Journal of Wenzhou Medical College
基金 温州医学院5010重大项目子课题
关键词 多发性骨髓瘤 成骨祖细胞 成骨分化 Mutiple myeloma osteoblast osteoblast differentiation
  • 相关文献

参考文献12

  • 1Roux C, Ravaud P, Coben-solal M,et al. Biologic histologic and densitometric effects of oral risedronate on bone in patients with multiplem yeloma[J].Bone, 1994,15 ( 1):41-49.
  • 2Melton LJ 3, Kyle RA,Achenbach SJ,et al.Fracture risk with multiple myeloma:a population-based study[J ].Bone Miner Res,2005,20(3):487-493.
  • 3Sezer O,Heider U,Zavrski I,et al. RANK ligand and osteoprotegerin in myeloma bone disease[J]. Blood,2003, 1 01 (6):2094-2098.
  • 4Theoleyre S,Couillaud C,Dunstan D,et al.Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF- κ B ligand and osteoprotegerin biological activities [J]. Experimental Cell Research, 2004,293(2):292-301.
  • 5Djulbegovic B,Wheatley K,Ross J,et al. Bisphosphonates in mutiple myeloma[J].Cochrane Database Syst Rev,2002, 3: CD003188.
  • 6Tian E, zhan FH, Walker R, et al.The Role of the WntSignaling Antagonist DKKI in the Development of Osteolytic Lesions in Multiple Myeloma [J]. The New England Journal of Medicine,2003, 349(26):2483-94.
  • 7Ehrlich LA, Chung HY, Ghobrial I et al.IL-3 is a potential inhibitor of osteoblast differentiation in mul-tiple myeloma [J] .Blood, 2006,106(4): 1407-1413.
  • 8Takashi Oshima, Masahiro Abe, Jin Asanoe,et al.Myeloma cells suppress bone formation by secreting a soluble Writ inhibitor, sFRP-2[J]. Blood,2005, 11 (1): 106-109.
  • 9Owen TA, AronowM, Shalhouh V, et al. Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiationduring formation of the bone extracellular matrix [J]. Cell Phsiol, 1990,143(3): 420-430.
  • 10Robinson JA, Harris SA, Riggs BL, et al. Estrogen regulation of human osteoblastic cell proliferation and differentiation[J]. Endocrinology, 1997, 138(7): 2919-2927.

同被引文献12

  • 1Roodman GD. New potential targets for treating myeloma bone disease[J].Clinical Cancer Research,2006,(20):6270-6273.
  • 2Voskaridou E,Christoulas D,Xirakia C. Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis.Reduction post-zoledronic acid administration[J].Haematologica,2009,(05):725-728.
  • 3Tian BS Fenghuang. The role of the wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma[J].New England Journal of Medicine,2003,(26):2483-2494.
  • 4Pearse RN,Sordillo EM,Yaccoby S. Multiple myeloma disrupts the TRANCE/osteopr-otegerin cytokine axis to trigger bone destruction and promote tumor progression[J].Proceedings of the National Academy of Sciences(USA),2001,(20):11581-11586.doi:10.1073/pnas.201394498.
  • 5Silvestris F,Lonbardi L,De Matteo M. Myeloma bone disease:pathogenetic mechanisms and clinical assessment[J].Leukemia Research,2007,(02):129-138.
  • 6Garderetl,Mazurierc,Chapela. Mesenchymal stem cell abnormalities in patients with multiple myeloma[J].Leukemia and Lymphoma,2007,(10):2032-2041.
  • 7Duncan AW,Rattis FM,DiMascio LN. Integration of Notch and Wnt Signaling in hematopoietic stem cell maintenance[J].Nat Immuno,2005,(3):314-322.doi:10.1038/ni1164.
  • 8Haber J,Abildgard N,Knudsenl M. Myeloma cell expression of 10 candidate genes for osteolytic bone disease.Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis[J].British Journal of Haematology,2008,(01):25-35.
  • 9Gunn WG,Conley A,Deininger L. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and Interleukin-6:a potential role in the development of lytic bone disease and tumor progression in multiple myeloma[J].Stem Cells,2006.986-991.
  • 10Hu Z,Peel SA,Ho SK. Role of bovine bone morphogenetic proteins in bone matrix protein and osteoblast-related gene expression during rat bone marrow stromal cell differentiation[J].Craniofac Surg,2005,(06):1006-1014.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部